Authors

Jason Westin, MD, MS, FACP, MD Anderson Cancer Center

Latest:

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Jason Westin, MD, The University of Texas MD Anderson Cancer Center

Latest:

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Jason Y. Cheng, PhD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Jatin J. Shah, MD

Latest:

Dr. Shah on Novel Therapies for Multiple Myeloma

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

Jatin J. Shah, MD, MD Anderson Cancer Center

Jatin J. Shah, MD, The University of Texas MD Anderson Cancer Center

Jatin P. Shah, MD, MD Anderson Cancer Center

Javier A. Pinilla-Ibarz, MD, PhD

Latest:

Dr. Pinilla-Ibarz on the Benefit of BTK Inhibitors in CLL

Javier Pinilla-Ibarz, MD, PhD, discusses the benefit of utilizing BTK inhibitors in chronic lymphocytic leukemia.

Javier A. Pinilla-Ibarz, MD, PhD, H. Lee Moffitt Cancer Center

Javier Cortes, MD, PhD

Latest:

Dr Cortés on Analyzing Outcomes With T-DXd in HER2+ Breast Cancer With Brain Metastases

Javier Cortés, MD, PhD, discusses the rationale for analyzing outcomes with trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Javier Munoz, MD, FACP, Banner MD Anderson Cancer Center

Javier Pinilla, MD, PhD

Latest:

Highlighting Key CML/ALL Data Presented at ASH 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Javier Pinilla-Ibarz, MD, PhD, H. Lee Moffitt Cancer Center

Javier Pinilla-Ibarz, MD, PhD, Moffitt Cancer Center

Javier Zulueta, MD

Latest:

Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

Jay Ciezki, MD

Latest:

Dr. Ciezki on Common Advanced Disease Sites in Patients

Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.

Jay D. Raman, MD

Latest:

Dr. Raman on Hematuria in Urothelial Cancer

Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.

Jay H. Fowke, PhD, MPH, MS

Latest:

Identifying Factors That Limit Access to Prostate Cancer Therapy

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses factors that can lead to disparity in access to prostate cancer therapy.

Jay Yang, MD

Latest:

Dr. Yang on the Current Treatment Landscape in MCL

Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.

Jaya V. Juturi, MD

Latest:

Do You Have the Right Tools?: How IT adoption can enhance your practice

True integration of cutting-edge care and timely translation of information from the bench to bedside requires an oncology practice to have knowledgeable physicians and a "toolbox of technology."